Literature DB >> 12148093

Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis.

Vikas R Dharnidharka1, Charles Kwon, Gary Stevens.   

Abstract

BACKGROUND: Serum cystatin C (Cys C) has been proposed as a simple, accurate, and rapid endogenous marker of glomerular filtration rate (GFR) in research and clinical practice. However, there are conflicting reports regarding the superiority of Cys C over serum creatinine (Cr), with a few studies suggesting no significant difference.
METHODS: We performed a meta-analysis of available data from various studies to compare the accuracy of Cys C and Cr in relation to a reference standard of GFR. A bibliographic search showed 46 articles until December 31, 2001. We also retrieved data from eight other studies presented and published in abstract form.
RESULTS: The overall correlation coefficient for the reciprocal of serum Cys C (r = 0.816; 95% confidence interval [CI], 0.804 to 0.826) was superior to that of the reciprocal of serum Cr (r = 0.742; 95% CI, 0.726 to 0.758; P < 0.001). Similarly, receiver operating characteristic (ROC)-plot area under the curve (AUC) values for 1/Cys C had greater identity with the reference test for GFR (mean ROC-plot AUC for Cys C, 0.926; 95% CI, 0.892 to 0.960) than ROC-plot AUC values for 1/Cr (mean ROC-plot AUC for serum Cr, 0.837; 95% CI, 0.796 to 0.878; P < 0.001). Immunonephelometric methods of Cys C assay produced significantly greater correlations than other assay methods (r = 0.846 versus r = 0.784; P < 0.001).
CONCLUSION: In this meta-analysis using currently available data, serum Cys C is clearly superior to serum Cr as a marker of GFR measured by correlation or mean ROC-plot AUC. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12148093     DOI: 10.1053/ajkd.2002.34487

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  435 in total

1.  Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury.

Authors:  Frank Dieterle; Elias Perentes; André Cordier; Daniel R Roth; Pablo Verdes; Olivier Grenet; Serafino Pantano; Pierre Moulin; Daniel Wahl; Andreas Mahl; Peter End; Frank Staedtler; François Legay; Kevin Carl; David Laurie; Salah-Dine Chibout; Jacky Vonderscher; Gérard Maurer
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

2.  A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function.

Authors:  Josef S Ozer; Frank Dieterle; Sean Troth; Elias Perentes; André Cordier; Pablo Verdes; Frank Staedtler; Andreas Mahl; Olivier Grenet; Daniel R Roth; Daniel Wahl; François Legay; Daniel Holder; Zoltan Erdos; Katerina Vlasakova; Hong Jin; Yan Yu; Nagaraja Muniappa; Tom Forest; Holly K Clouse; Spencer Reynolds; Wendy J Bailey; Douglas T Thudium; Michael J Topper; Thomas R Skopek; Joseph F Sina; Warren E Glaab; Jacky Vonderscher; Gérard Maurer; Salah-Dine Chibout; Frank D Sistare; David L Gerhold
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

3.  Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.

Authors:  Kajs-Marie Schützer; Maria K Svensson; Sofia Zetterstrand; Ulf G Eriksson; Karin Wåhlander
Journal:  Eur J Clin Pharmacol       Date:  2010-06-10       Impact factor: 2.953

4.  Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass.

Authors:  Catherine D Krawczeski; Rene G Vandevoorde; Thelma Kathman; Michael R Bennett; Jessica G Woo; Yu Wang; Rachel E Griffiths; Prasad Devarajan
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

Review 5.  Commentary: clinical diagnostic use of cystatin C.

Authors:  Davis Massey
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

6.  Homocysteine levels and risk of hip fracture in postmenopausal women.

Authors:  Meryl S Leboff; Rupali Narweker; Andrea LaCroix; Lieling Wu; Rebecca Jackson; Jennifer Lee; Douglas C Bauer; Jane Cauley; Charles Kooperberg; Cora Lewis; Asha M Thomas; Steven Cummings
Journal:  J Clin Endocrinol Metab       Date:  2009-01-27       Impact factor: 5.958

7.  Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study.

Authors:  Michelle C Odden; Rebecca Scherzer; Peter Bacchetti; Lynda Anne Szczech; Stephen Sidney; Carl Grunfeld; Michael G Shlipak
Journal:  Arch Intern Med       Date:  2007-11-12

8.  Body mass index and preclinical kidney disease in Indian adults aged 40 years and above without chronic kidney disease.

Authors:  Charumathi Sabanayagam; Tien Yin Wong; Jiemin Liao; Sunil Sethi; Boon Wee Teo
Journal:  Clin Exp Nephrol       Date:  2014-02-14       Impact factor: 2.801

9.  Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial.

Authors:  Horng H Chen; Omar F AbouEzzeddine; Kevin J Anstrom; Michael M Givertz; Bradley A Bart; G Michael Felker; Adrian F Hernandez; Kerry L Lee; Eugene Braunwald; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2013-09-01       Impact factor: 8.790

Review 10.  Screening for chronic kidney disease in HIV-infected patients.

Authors:  Michelle M Estrella; Derek M Fine
Journal:  Adv Chronic Kidney Dis       Date:  2010-01       Impact factor: 3.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.